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Abstract
Background: Antibodies to the water channel protein aquaporin-4 (AQP4), which is expressed in astrocytic endfeet at the
blood brain barrier, have been identified in the serum of Neuromyelitis optica (NMO) patients and are believed to induce
damage to astrocytes. However, AQP4 specific T helper cell responses that are required for the generation of anti-AQP4
antibodies and most likely also for the formation of intraparenchymal CNS lesions have not been characterized.
Methodology/Principal Findings: Using overlapping 15-meric peptides of AQP4, we identified the immunogenic T cell
epitopes of AQP4 that are restricted to murine major histocompatibility complex (MHC) I-A
b. The N-terminal region of AQP4
was highly immunogenic. More precisely, the intracellular epitope AQP422–36 was detected as major immunogenic
determinant. AQP482–108 (located in the second transmembrane domain), AQP4139–153 (located in the second extracellular
loop), AQP4211–225 (located in the fifth transmembrane domain), AQP4235–249 (located in the sixth transmembrane domain),
as well as AQP4289–306 in the intracellular C-terminal region were also immunogenic epitopes. AQP422–36 and AQP4289–303
specific T cells were present in the natural T cell repertoire of wild type C57BL/6 mice and T cell lines were raised. However,
active immunization with these AQP4 peptides did not induce signs of spinal cord disease. Rather, sensitization with AQP4
peptides resulted in production of IFN-c, but also IL-5 and IL-10 by antigen-specific T cells. Consistent with this cytokine
profile, the AQP4 specific antibody response upon immunization with full length AQP4 included IgG1 and IgG2, which are
associated with a mixed Th2/Th1 T cell response.
Conclusions and Significance: AQP4 is able to induce an autoreactive T cell response. The identification of I-A
b restricted
AQP4 specific T cell epitopes will allow us to investigate how AQP4 specific autoimmune reactions are regulated and to
establish faithful mouse models of NMO that include both cellular and humoral responses against AQP4.
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Introduction
Neuromyelitis optica (Devic syndrome) is a severe inflammatory
demyelinating syndrome affecting optic nerves and spinal cord [1].
The detection of NMO-IgG antibodies in the sera of patients with
clinically defined NMO but not in patients with multiple sclerosis
(MS), gave rise to the concept that NMO might be a distinct
disease entity [2]. NMO-IgG reacts against aquaporin-4 (AQP4), a
water channel protein that is highly expressed in astrocytic endfeet
of the glia limitans [3]. AQP4 is expressed in the CNS, skeletal
muscle, lung, kidney, stomach, and exocrine glands (for review see
[4]). In the CNS, AQP4 is the main water channel and besides its
abundance in astrocytes at the blood/parenchyma barrier, is also
expressed in ependymal cells at the CSF/parenchyma barrier.
AQP4 KO mice are protected from conditions associated with
cytotoxic edema like experimental stroke, but do worse in response
to vasogenic edema like in brain tumor models [5,6]. These data
suggest that AQP4 has a role in removing excess water from the
CNS interstitial space either by uptake into glial cells or
transepithelial transport.
AQP4 has two translational isoforms: a long isoform (M1) in
which translation is initiated at Met-1 and a short isoform (M23) in
which translation is initiated at Met-23 [7]. M1 and M23 possess 6
putative transmembrane domains with intracellular N- and C-
terminal regions and form either homo or heterotetramers [8].
However, only M23 is arranged in large orthogonal arrays of
particles (OAP) in the plasma membrane of AQP4 expressing cells
[9]. In an mRNA expression study, it has been suggested that M1
and M23 might be differentially expressed in various parts of the
CNS with M1 prevailing in the optic nerve and spinal cord and
M23 in the brain and cerebellum [10]. It is not known whether
M1 and M23 are also differentially targeted by NMO-IgG in vivo,
which could explain in part the lesion distribution in the spinal
cord and optic nerves of NMO patients.
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16083Since the majority (60 to 70%) of patients that are diagnosed
with NMO according to clinical criteria are positive for anti-AQP4
antibodies of the IgG1 isotype [2,11,12], the presence of NMO-
IgG has been incorporated in the diagnostic criteria for NMO
[13]. The diagnositic sensitivity and specificity of serum NMO-
IgG have been reported to be in the range of 80 to 90% depending
on the assay system [2,11,14]. Several recent studies were designed
to test whether NMO-IgG, beyond its invaluable role as
biomarker, was also pathogenetically relevant in NMO. The
rationale was that NMO-IgG recognizes an extracellular epitope
of AQP4, binds to complement, and leads to the internalization of
AQP4 in vitro [15]. In addition, plasmapheresis is a beneficial
treatment strategy in NMO patients [16]. Indeed, anti-AQP4
IgG1 has now been shown to cause damage to astrocytes in vivo as
well. First, anti-AQP4-IgG1 and complement deposition can be
found in CNS lesions of NMO patients [17,18]. Second, binding
of anti-AQP4 IgG is associated with loss of AQP4 expression and
damage to astrocytes [18,19,20]. Third, systemic adoptive transfer
of AQP4 specific IgG antibodies engineered from intrathecal
clones of NMO patients or NMO-IgG serum fractions from
patients but not AQP4-preabsorbed serum IgG were able to
induce additional perivascular astrocyte loss in experimental rats
that had been pretreated with activated myelin specific CD4
+ T
cells to induce disrupture of the blood brain barrier that by itself
was subclinical or only mildly symptomatic [21,22,23]. Together,
these results suggest that NMO-IgG might be involved in the
pathogenic process of NMO.
However, the lesions that could be induced in experimental
animals by transfer of NMO-IgG lacked the longitudinally extensive
properties and parenchymal involvement including myelinolysis that
Table 1. Overlapping AQP4 peptides.
No AA Sequence No AA Sequence No AA Sequence
1 1–15 MSDRPTARRWGKCGP 36 106–120 CTRKISIAKSVFYIA 71 211–225 SMNPARSFGPAVIMG
2 4–18 RPTARRWGKCGPLCT 37 109–123 KISIAKSVFYIAAQC 72 214–228 PARSFGPAVIMGNWE
3 7–21 ARRWGKCGPLCTREN 38 112–126 IAKSVFYIAAQCLGA 73 217–231 SFGPAVIMGNWENHW
4 10–24 WGKCGPLCTRENIMV 39 115–129 SVFYIAAQCLGAIIG 74 220–234 PAVIMGNWENHWIYW
5 13–27 CGPLCTRENIMVAFK 40 118–132 YIAAQCLGAIIGAGI 75 223–237 IMGNWENHWIYWVGP
6 16–30 LCTRENIMVAFKGVW 41 121–135 AQCLGAIIGAGILYL 76 226–240 NWENHWIYWVGPIIG
7 19–33 RENIMVAFKGVWTQA 42 124–138 LGAIIGAGILYLVTP 77 229–243 NHWIYWVGPIIGAVL
8 22–36 IMVAFKGVWTQAFWK 43 127–141 IIGAGILYLVTPPSV 78 232–246 IYWVGPIIGAVLAGG
9 25–39 AFKGVWTQAFWKAVT 44 130–144 AGILYLVTPPSVVGG 79 235–249 VGPIIGAVLAGGLYE
10 28–42 GVWTQAFWKAVTAEF 45 133–147 LYLVTPPSVVGGLGV 80 238–252 IIGAVLAGGLYEYVF
11 31–45 TQAFWKAVTAEFLAM 46 136–150 VTPPSVVGGLGVTMV 81 241–255 AVLAGGLYEYVFCPD
12 34–48 FWKAVTAEFLAMLIF 47 139–153 PSVVGGLGVTMVHGN 82 244–258 AGGLYEYVFCPDVEF
13 37–51 AVTAEFLAMLIFVLL 48 142–156 VGGLGVTMVHGNLTA 83 247–261 LYEYVFCPDVEFKRR
14 40–54 AEFLAMLIFVLLSLG 49 145–159 LGVTMVHGNLTAGHG 84 250–264 YVFCPDVEFKRRFKE
15 43–57 LAMLIFVLLSLGSTI 50 148–162 TMVHGNLTAGHGLLV 85 253–267 CPDVEFKRRFKEAFS
16 46–60 LIFVLLSLGSTINWG 51 151–165 HGNLTAGHGLLVELI 86 256–270 VEFKRRFKEAFSKAA
17 49–63 VLLSLGSTINWGGTE 52 154–168 LTAGHGLLVELIITF 87 259–273 KRRFKEAFSKAAQQT
18 52–66 SLGSTINWGGTEKPL 53 157–171 GHGLLVELIITFQLV 88 262–276 FKEAFSKAAQQTKGS
19 55–69 STINWGGTEKPLPVD 54 160–174 LLVELIITFQLVFTI 89 265–279 AFSKAAQQTKGSYME
20 58–72 NWGGTEKPLPVDMVL 55 163–177 ELIITFQLVFTIFAS 90 268–282 KAAQQTKGSYMEVED
21 61–75 GTEKPLPVDMVLISL 56 166–180 ITFQLVFTIFASCDS 91 271–285 QQTKGSYMEVEDNRS
22 64–78 KPLPVDMVLISLCFG 57 169–183 QLVFTIFASCDSKRT 92 274–288 KGSYMEVEDNRSQVE
23 67–81 PVDMVLISLCFGLSI 58 172–186 FTIFASCDSKRTDVT 93 277–291 YMEVEDNRSQVETDD
24 70–84 MVLISLCFGLSIATM 59 175–189 FASCDSKRTDVTGSI 94 280–294 VEDNRSQVETDDLIL
25 73–87 ISLCFGLSIATMVQC 60 178–192 CDSKRTDVTGSIALA 95 283–297 NRSQVETDDLILKPG
26 76–90 CFGLSIATMVQCFGH 61 181–195 KRTDVTGSIALAIGF 96 286–300 QVETDDLILKPGVVH
27 79–93 LSIATMVQCFGHISG 62 184–198 DVTGSIALAIGFSVA 97 289–303 TDDLILKPGVVHVID
28 82–96 ATMVQCFGHISGGHI 63 187–201 GSIALAIGFSVAIGH 98 292–306 LILKPGVVHVIDVDR
29 85–99 VQCFGHISGGHINPA 64 190–204 ALAIGFSVAIGHLFA 99 295–309 KPGVVHVIDVDRGEE
30 88–102 FGHISGGHINPAVTV 65 193–207 IGFSVAIGHLFAINY 100 298–312 VVHVIDVDRGEEKKG
31 91–105 ISGGHINPAVTVAMV 66 196–210 SVAIGHLFAINYTGA 101 301–315 VIDVDRGEEKKGKDQ
32 94–108 GHINPAVTVAMVCTR 67 199–213 IGHLFAINYTGASMN 102 304–318 VDRGEEKKGKDQSGE
33 97–111 NPAVTVAMVCTRKIS 68 202–216 LFAINYTGASMNPAR 103 307–321 GEEKKGKDQSGEVLS
34 100–114 VTVAMVCTRKISIAK 69 205–219 INYTGASMNPARSFG 104 309–323 EKKGKDQSGEVLSSV
35 103–117 AMVCTRKISIAKSVF 70 208–222 TGASMNPARSFGPAV
doi:10.1371/journal.pone.0016083.t001
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complement were co-injected directly into the brain in a traumatic
approach [23]. Furthermore, intravenous or intraperitoneal transfer
of immunoglobulin fractions from NMO patients did not induce
astrocytic damage in laboratory animals whose blood brain barrier
was leaky in the absence of inflammatory stimuli [22] suggesting that
lesion development in NMO may not exclusively rely on effector
functions of NMO-IgG. In addition, the generation of anti-AQP4
antibodies of the IgG1 isotype in the peripheral immune compart-
ment inevitably requires class-switch recombination in antigen
specific B cells and thus cognate T cell help [24,25]. Therefore, we
hypothesized that there must be an anti-AQP4 specific T cell
response in NMO. In the present study, we tested the immunoge-
nicity of AQP4 in C57BL/6 mice and identified the major I-A
b
restricted immunogenic determinants of AQP4. These data might
build the foundation to develop animal models for NMO that include
both antigen specific T cell and B cell mediated immunopathology.
Results
Identification of I-A
b restricted epitopes of AQP4
In humans, AQP4 specific NMO immunoglobulins belong to
the IgG1 isotype. Less than 10% of NMO patients have serum
IgM antibodies to AQP4 in addition to NMO-IgG1. Thus, class
switch recombination must have taken place. A cognate T cell
response to AQP4 resulting in subsequent B cell help is required in
order to perform the isotype switch from IgM to IgG1. We wanted
to characterize the T cell response against AQP4 protein. Thus,
we generated lysates from LN18 cells engineered to overexpress
full length human AQP4 by lentiviral transduction and purified
AQP4 [26]. AQP4 is a highly conserved protein and the protein
sequence identity between human and mouse AQP4 M1 and M23
translational isoforms is 92.9% and 94.7%, respectively.
Full length AQP4 emulsified in CFA was used to immunize wild
type C57BL/6 mice (I-A
b). Draining lymph node cells and splenocytes
were isolated and restimulated in vitro with pools of overlapping 15-
meric peptides spanning the entire M1 AQP4 protein sequence
(Tables 1 and 2). While the strongest proliferative response was
detected upon restimulation with peptide pool 17 (Fig. 1A), the
stimulation indices were only in the range of 1.1 to 3.0 (Fig. 1A). Thus,
we decided to restimulate each pool with its individual peptides in a
second round. Irradiated syngeneic (H-2K
b,H - 2 D
b,I - A
b) splenocytes
were used as APCs. Any 15-meric peptide that yielded proliferative
responses of at least 3 fold above background was considered as
potentially immunogenic in the context of I-A
b ( F i g .1 B ) .R o b u s t
proliferative T cell responses were obtained upon restimulation with
epitopes derived from AQP48–54 (peptides 3, 8, 9, 10, 12, 14), AQP482–
108 (peptides 28, 31, 32), AQP4139–153 (peptide 47), AQP4211–225
(peptide 71), AQP4235–249 (peptide 79), and AQP4289–306 (peptides 97,
98) (Fig. 1B). N-terminal peptide epitopes of AQP4 induced the
strongest recall responses (Fig. 1B) suggesting that the N-terminal
region of AQP4 comprises the most robust immunogenic I-A
b
restricted T cell epitopes (Fig. 2A). The core immunogenic N-terminal
determinant of AQP4 (AQP422–36=peptide 8) is common to both the
M1 and M23 translational isoforms of AQP4, except for the isoleucine
at positon 22, which is absent in the M23 isoform of AQP4. The amino
acid sequence of AQP422–36 is identical between human and mouse
while there is only minimal amino acid variance between human and
mouse in the additional I-A
b restricted AQP4 epitopes (Fig. 2B). Thus,
AQP4 is immunogenic in the I-A
b context and wild type C57BL/6
mice harbor autoreactive AQP4 specific T cells in their natural
repertoire.
Characterization of AQP422–36 specific T cell lines
AQP422–36 proved to be immunodominant and the proliferative
response of short term T cell cultures from lymph node cells of
AQP422–36 immunized mice were very robust (Fig. 3A). In order
to qualitatively characterize AQP422–36 specific T cell responses,
we tested the cytokine profile of lymph node cells from AQP422–
36/CFA-sensitized mice upon restimulation with AQP422–36 in
vitro. Although we used CFA as adjuvant, the first rounds of
peptide specific restimulation of lymph node cells under neutral
conditions yielded mixed Th1/Th2 cytokine responses (Fig. 3B).
We observed production of IL-2, IFN-c, TNF, GM-CSF, IL-6,
but also IL-4 and large amounts of IL-5 and IL-10 while IL-17 was
not detectable (Fig. 3B). About one third of the responding T cells
were IFN-c
+IL-10
+ and close to one half were IFN-c
+IL-5
+
(Fig. 3C). Together, these data suggest that in our experimental
system, AQP422–36 induced the expansion of T cells with a unique
cytokine profile that was characterized by co-expression of large
amounts of Th1 and Th2 associated cytokines.
Immunization with AQP4 peptides does not induce
clinical disease
AQP4 specific T cell responses were characterized by a mixed
Th1/Th2 phenotype. We predicted that the exaggerated IL-10
production by AQP422–36 specific T cells would prevent T cell driven
immunopathology in AQP4 immunized animals. In order to test
whether active immunization with AQP4 in CFA was able to induce
clinical signs of central nervous damage, we sensitized C57BL/6 mice
with full length AQP4/CFA, AQP422–36 (peptide 8)/CFA, or
AQP4289–303 (peptide 97)/CFA plus administration of pertussis toxin
a n dfo ll o w e dt h ea n i ma l sfo r4w e e k s .Wh i lea llm i c ei naM O G 35–55/
CFA immunized control group developed severe EAE, none of the
AQP4 immunization protocols resulted in the induction of a clinically
manifest spinal cord disease or signs of visual impairment (Fig. 4A).
Neither did we observe weight loss or signs of kidney disease. The
animals remained apparently healthy and after four weeks were
subjected to histological work-up. Here, neither cellular infiltrates nor
myelinlosswereidentifiedinthespinalcordsoropticnervesofAQP4
peptide immunized animals (Fig. 4B, C). Thus, despite a strong
antigen specific T cell response against AQP4, the animals remained
protected from immunopathology in AQP4 expressing tissues.
T helper cell responses to AQP4 shape a specific AQP4
specific IgG response pattern
We wished to validate whether the cytokine pattern of AQP4
specific T cell responses was relevant to the adaptive immune
Table 2. Peptide pools.
Pool 1234567891 0 1 1
12 135791 1 1 3 1 5 1 7 1 9 2 1
13 23 25 27 29 31 33 35 37 39 41 43
14 45 47 49 51 53 55 57 59 61 63 65
15 67 69 71 73 75 77 79 81 83 85 87
16 89 91 93 95 97 99 101 103 2 4 6
17 8 1 01 21 41 61 82 02 22 42 62 8
18 30 32 34 36 38 40 42 44 46 48 50
19 52 54 56 58 60 62 64 66 68 70 72
20 74 76 78 80 82 84 86 88 90 92 94
21 96 98 100 102 104
doi:10.1371/journal.pone.0016083.t002
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responses can be determined in vivo by measuring the IgG subtypes
that are produced by antigen specific B cells in a T helper cell
dependent manner. It is known that in mice, Th1 biased T helper
cell responses favor the production of antigen specific IgG2a and
IgG3 while Th2 responses prompt B cells to undergo class switch
recombination towards IgG1 and IgE [24,25,27]. Immunization
with AQP4 protein/CFA but not with MOG35–55/CFA evoked a
robust anti-AQP4 IgG response which was measured in the sera of
sensitized mice (Fig. 5A). While AQP4 specific IgA, IgE, and IgM
could not be detected, the dominant IgG subclasses were IgG1,
IgG2a, and IgG2b but not IgG3 (Fig. 5B, C) indicating that the T
helper cell response to AQP4/CFA in this immunization regimen
was a mixed Th1/Th2 response in vivo as well.
In summary, these data suggest that the antibody response to
AQP4 is T cell-dependent. Both direct analysis of T cell responses
to AQP4 and measurement of antigen specific Ig subclass patterns
in vivo highlight a mixed Th1/Th2 response upon immunization
with AQP4 protein.
Discussion
In the present study, we provide evidence that an autoreactive T
cell response against AQP4 can be induced in C57BL/6 mice and
Figure 1. Screening of T cell responses with pools of AQP4 peptides. Mice were immunized with full length AQP4 protein/CFA. Draining
lymph node cells and splenocytes were restimulated in vitro with pools of overlapping AQP4 peptides (Tables 1 and 2). (A) Proliferative responses of
AQP4-sensitized lymphocytes to 21 pools of overlapping AQP4 peptides as measured by
3[H] thymidine incorporation (c.p.m.). Mean of triplicate
cultures + SD or stimulation indices as calculated by deviding the c.p.m. values of each peptide pool by the background c.p.m. This experiment was
performed twice with similar results. (B) In a second round of restimulation, T cells out of each pool were stimulated with the individual peptides of
the parental pool in the presence of irradiated syngeneic splenocytes as APCs. Proliferative responses of T cell pools that showed antigen specific
responses to at least one individual splenocytes with a stimulation index of at least 3.0 are depicted. Mean of
3[H] thymidine incorporation (c.p.m.) of
triplicate cultures + SD are shown.
doi:10.1371/journal.pone.0016083.g001
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b restricted epitopes of AQP4 and sequence homology of human vs mouse AQP4. (A) Topological
model of AQP4 (M1 translational isoform) according to Crane and coworkers [8]. The core immunogenic (I-A
b restricted) determinant of AQP4 in the
N-terminus is highlighted in dark blue. The remainder of the immunogenic T cell epitopes is highlighted in cyan. The numbers indicate the amino
acid residue position in the AQP4 protein sequence. (B) Amino acid sequence alignment of human and mouse AQP4 M1 isoforms. I-A
b restricted T cell
determinants are highlighted (cyan). The dominant immunogenic epitope is represented by peptide 8 as indicated by a box (peptide sequence in
dark blue). T cell epitopes common to M1 and M23 isoforms of AQP4 are underlined. Asterisks indicate sequence identity at the corresponding
sequence position.
doi:10.1371/journal.pone.0016083.g002
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16083Figure 3. Functional characterization of AQP422–36 peptide specific TCL8.2. Representative T cell line (TCL) reactive to AQP422–36. (A) TCL8.2
cells were restimulated with irradiated syngeneic splenocytes in the presence of increasing concentrations of AQP422–36. The proliferative response
was determined by
3[H] thymidine incorporation. Mean c.p.m. of triplicate cultures + SD. (B) Cytokine production of TCL8.2 cells in response to
increasing concentrations of AQP422–36 as measured by cytometric bead array in the cell culture supernatant collected at 48 h after initiation of
restimulation. Mean cytokine concentrations + SD of triplicate cultures. (C) Intracellular cytokine staining of TCL8.2 after 6 restimulation cycles.
doi:10.1371/journal.pone.0016083.g003
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b restricted T cell epitopes. While AQP422–36
is thedominant T cell epitope, thereareotherimmunogenicregions
in the AQP4 sequence. With the exception of the isoleucine at
position 22 of AQP422–36, all T cell epitopes are contained in both
M1 and M23 translational isoforms of AQP4. The AQP4 specific T
cell response likely accounts for the T cell supported class switch
recombination of AQP4 specific B cells and the production of anti-
AQP4 IgG type antibodies.
Recent attempts to prove the pathogenic relevance of NMO-
IgG have focused on rats as recipients of purified IgG fractions
from NMO-patients because rat but not mouse complement binds
to purified human NMO-IgG [23] and thus, NMO-IgG
dependent CNS damage can easier be shown in recipient rats
than in mice receiving human serum IgG. Indeed, passive transfer
of NMO-IgG or engineered monoclonal antibodies against AQP4
resulted in extinction of AQP4 in astrocytic endfeet and perhaps in
astrocyte loss [21,22]. Myelin specific T cell blasts but not non-
inflammatory stimuli were able to promote the pathogenic
potential of NMO-IgG presumably by disrupting the blood brain
barrier. In contrast, a recent report suggested that upon
immunization with CFA alone, i. e. in the absence of a CNS-
antigen specific T cell response, astrocyte damage could be
induced by transfer of IgG fractions from NMO patients [28].
However, in all these transfer experiments, the CNS lesions
induced by NMO-IgG were distinct from lesions found in human
Devic’s patients and in particular, failed to recapitulate a vast
extent of demyelination [17].
We believe that the identification of the AQP4 determinants that
evoke I-A
b restricted T cell responses is a further step towards the
development of an animal model for Devic’s disease that would
incorporate both T cell and B cell mediated anti-AQP4 responses.
The current concept of neuromyelitis optica is based on the idea
that this disease might be an astrocyte disease with astrocytic AQP4
as a major molecular target of the adaptive immune response. We
proposed that there must be an anti-AQP4 T cell response to
account for the induction of class switched antibodies to AQP4.
Here, we identified T cell epitopes of AQP4 in the context of I-A
b.
AQP4 specific T cell responses were elicited in wild type mice.
Thus, our data suggest that - similar to other autoantigens - thymic
deletional tolerance against AQP4 is incomplete. T cell lines raised
against AQP422–36, the major immunogenic epitope of AQP4,
produced IFN-c but were consistently also characterized by
simultaneous secretion of Th2 associated cytokines. Accordingly,
immunization with full length AQP4 protein induced a T cell
dependent AQP4 specific antibody response whose Ig class and
subclass pattern was reminiscent of a mixed Th1/Th2 reaction.
Although T cell tolerance against AQP4 is broken upon
immunization with AQP4/CFA, it is likely that AQP4 directed
immunopathology is limited due to T cell derived IL-10. We are
currently testing this hypothesis in further experiments.
Excellent animal models that include both CNS antigen specific
T and B cell responses have recently been developed for MOG as
target autoantigen. Transgenic mice that harbor both MOG
specific T cells and MOG specific B cells develop a severe
opticospinal syndrome and were proposed to mimic certain
aspects of Devic’s disease [29,30]. Many aspects of the cooperation
between T and B cells, namely the capacity of antigen specific B
cells to function as APCs for T cells of the same specificity, were
extensively investigated in these animal models. In addition, MOG
specific T cell driven immunopathology in the CNS appears to
recruit MOG specific B cells from the natural repertoire to
develop into antibody producing cells and contribute to lesion
development by MOG specific antibodies [31]. These data
highlight the pathogenic importance of a CD4
+ T helper cell
response to an autoantigen that is identical or locally linked to the
respective B cell autoantigen. However, with the discovery and
validation of NMO-IgG in reductionist in vitro and in vivo models, it
has become evident that astrocytic AQP4 may be the relevant
target autoantigen in neuromyelitis optica instead of MOG which
is expressed by oligodendrocytes [32].
The characterization of the I-A
b restricted AQP4 T cell
epitopes, will now allow us to investigate the mechanisms that
result in the breach of immunological tolerance against AQP4 and
also why immunopathology develops in the CNS while other
AQP4 expressing tissues are relatively spared. Based on the
current results, we may be able to construct animal models in mice
that may give us insight in the pathogenic cascade of autoimmune
inflammatory astrocyte diseases and perhaps help us to understand
how astrocyte targeted T and B cell responses ultimately lead to
extensive CNS lesions.
Materials and Methods
Aquaporin-4 protein expression and purification
The human M1 variant of AQP4 protein was stably
overexpressed in LN18 cells (LN18
AQP4) by lentiviral transfection
as described previously [26]. In order to generate AQP4 protein,
cells were grown at large scale and proteins were extracted from
LN18
AQP4 cells by using mammalian protein extraction reagent
buffer (Thermo Scientific) according to the manufacturer’s
recommendations. AQP4 protein was isolated by column-based
affinity purification using a polyclonal rabbit anti human-AQP4
antibody (Sigma) coupled to cyanogen bromide-activated sephar-
ose 4B according to the manufacturer’s instructions (Amersham
pharmaci). Yield and purity of the protein preparation was tested
by coomassie staining and western blot of SDS-PAGE gels.
Peptide antigens
Mouse MOG35–55 (MEVGWYRSPFSRVVHLYRNGK) and
human AQP422–36 (IMVAFKGVWTQAFWK) as well as human
AQP4289–303 (TDDLILKPGVVHVID) were synthesized by
Auspep Pty Ltd (Parkville, Victoria, Australia) and JPT Peptide
Technology (Berlin, Germany), respectively. Overlapping peptides
(15-mers) of full length human AQP4 protein (M1 isoform) were
synthesized by JPT Peptide Technology according to Table 1.
Mice and immunization procedures
Wild type C57BL/6 mice (H-2K
b, H-2D
b, I-A
b) at 8 weeks of
age were immunized subcutaneously with an emulsion of antigen
in complete Freund’s adjuvant (CFA) with a final concentration of
Figure 4. Immunization of C57BL/6 mice with AQP422–36 or AQP4289–303 does not induce signs of spinal cord disease or optic neuritis.
Groups of wild type C57BL/6 mice (n=4 per group) were immunized with PBS/CFA, MOG35–55/CFA, AQP422–36 (peptide 8)/CFA, or AQP4289–303 (peptide
97)/CFA. (A) EAE scores. Note that AQP4 peptide immunized mice did not develop signs of disease while MOG35–55/CFA immunized animals showed
classical paraparesis. (B, C) Mice that had been immunized with MOG35–55/CFA, AQP422–36 (peptide 8)/CFA, or AQP4289–303 (peptide 97)/CFA were
analysedbyhistology. Representativesectionsofspinalcords (B)andoptic nerves(C) areshown.Paraffinsectionswere stainedwithluxolfast blue (LFB)-
PAS to illustrate demyelination or with antibodies to CD3 or Mac-3 to visualize T cell or macrophage infiltrates, respectively. Spinal cord areas that are
shown at higher magnification are marked by frames. Scale bars are 500 mm and 200 mm for the spinal cord sections and 100 mm for the optic nerve
sections as indicated.
doi:10.1371/journal.pone.0016083.g004
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contained final antigen concentrations of 1 mg/ml for MOG35–55
peptide, AQP422–36 peptide, AQP4289–303 peptide, or AQP4
protein, respectively. Each mouse received a total volume of
100 ml of immunization inoculum corresponding to 100 mgo f
antigen as subcutaneous injections at the base of the tail. In
addition, mice were administered 200 ng pertussis toxin in PBS i.
p. on days 0 and 2 after immunization. When immunized with full
length AQP4 protein, mice received a booster immunization with
AQP4 protein/CFA (in the absence of additional pertussis toxin)
after 4 weeks. Where indicated, clinical signs of EAE were assessed
according to following score: 0, no sings of disease; 1, loss of tone
Figure 5. Antibody response to AQP4. Wild type C57BL/6 mice were immunized with full length AQP4/CFA as described in Materials and
Methods. Unimmunized mice or mice immunized with MOG35–55/CFA were used as controls. Sera of mice from each group were collected and tested
for AQP4 specific antibodies in a cell based flow cytometry analysis. Subclass specification was performed by using fluorochrome labeled anti-mouse
Ig antibodies specific for IgM, IgA, IgE, IgG1, IgG2a, IgG2b, and IgG3 (FITC labeled) or total IgG H+L (AlexaFluor488 labeled). (A) Representative
histogram plots illustrating the MFIs for AQP4 specific IgG H+L in the various test groups. (B) Representative histogram plots of AQP4 specific Ig
classes and IgG subclasses in AQP4 immunized animals. (C) DMFIs + SEM (n=4) for AQP4 specific IgG H+L in naive control mice, MOG35–55 immunized
mice, or full length AQP4 immunized mice. (D) DMFIs + SEM (n=4) for individual anti-AQP4 Ig classes and IgG subclasses in full length AQP4
immunized mice.
doi:10.1371/journal.pone.0016083.g005
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tetraplegia; 5, moribund. Mice were kept in a pathogen free facility
at the Neurological Department of the Technical University
Munich. The animal protocol was approved by the animal welfare
committee of the Bavarian state authorities (Tierschutzkommission
der Regierung von Oberbayern, Munich, Germany, License
number: 55.2-1-54-2531-88-08). All experiments were carried out
in accordance with the guidelines prescribed by the Bavarian state
authorities.
AQP4 peptide pool screening, antigen specific
restimulation and proliferation assays
Draining lymph node cells and splenocytes were isolated from
full length AQP4/CFA-immunized mice on day 6 after the
booster immunization. Peptide pools were generated according to
Table 2 with each peptide at a final concentration of 10 mg/ml. In
a 96 well format, suspensions of 400,000 in vivo sensitized mixed
lymph node and spleen cells were re-stimulated for 72 h in vitro
with individual peptide pools in DMEM/10% FCS supplemented
with 5610
25 M b-mercaptoethanol, 1 mM sodium pyruvate,
non-essential amino acids, L-glutamine, and 100 U penicillin/
100 mg streptomycin per ml (clone medium). During the last 16 h,
cells were pulsed with 1 mCi of
3[H]thymidine (PerkinElmer)
followed by harvesting on glass fiber filters and analysis of
incorporated
3[H]thymidine in a b-counter (1450 Microbeta,
Trilux, PerkinElmer). In a parallel set-up, peptide pool restimu-
lations were supplementated with recombinant mouse IL-2 at
2 ng/ml (R&D systems). After 14 days, cells from each peptide
pool were divided in aliquots and each aliquot was restimulated in
clone medium with a single peptide out of the parental pool at a
concentration of 10 mg/ml in clone medium in the presence of
irradiated (3000 rad) splenic APCs isolated from naive C57BL/6
mice. After 48 h, supernatants were collected for cytokine
measurement and proliferation was determined by
3[H]thymidine
incorporation as described.
T cell lines specific for immunogenic determinants of AQP4
were generated from draining lymph node cells isolated 2 weeks
after immunization from mice immunized with AQP422–36/CFA
or AQP4289–303/CFA. In cyclic recall stimulations, draining
lymph node cells were stimulated with AQP422–36 or AQP4289–303
in clone medium in the presence of irradiated syngeneic splenic
APCs. Restimulation cycles with irradiated splenic APCs were
repeated every 10 to 12 days to obtain antigen specific T cell lines.
In order to propagate the T cell lines, recombinant mouse IL-2
was added at a concentration of 2 ng/ml 72 h after set-up of
antigen specific recall cultures.
Cytokine profiling of AQP4 peptide specific T cell lines
Supernatants of antigen specific T cell lines were assessed for
cytokine concentrations with standard ELISA technique (R&D
systems) or cytometric bead array (Bender systems) according to
the manufacturers’ recommendations. For intracellular cytokine
staining, AQP4 peptide specific T cell lines were stimulated in
clone medium containing phorbol 12-myristate 13-acetate (PMA,
50 ng/ml, Sigma), ionomycin (1 mg/ml, Sigma), and monensin
(GolgiStop 1 ml/ml, BD Biosciences) at 37uC/10% CO2 for 4 h.
After staining of surface markers, cells were fixed and permeabi-
lized (Cytofix/Cytoperm and Perm/Wash buffer, BD Biosciences)
followed by staining with monoclonal antibodies to mouse IL-4,
IL-5, IL-10, IL-17, and IFN-c, (all obtained from BD Biosciences)
and fluorocytometric analysis (CYAN, Beckmann/Coulter).
Determination of anti-AQP4 antibody subtypes in mouse
sera of immunized mice
To determine antibody titres and Ig subtypes against AQP4,
sera were collected from PBS/CFA-, MOG35–55/CFA-, or AQP4
protein/CFA-immunized mice. Serum samples were taken 3
months after initial sensitization of mice. Sera were diluted in 1: 50
in PBS 1% FCS and applied for detection of conformational
antibodies to AQP4 in a cell based assay previously described [26].
Briefly, AQP4 transduced LN18 cells (LN18
AQP4) or control
transduced LN18 cells (LN18
CTR) were exposed to the diluted
sera. Ig subclasses were identified by using AlexaFluor488 labelled
secondary antibodies to mouse IgG H+L (Invitrogen) or FITC
labeled anti-IgM, -IgA, -IgE, -IgG1, -IgG2a, -IgG2b, or -IgG3,
(Serotec). Staining of LN18
AQP4 or control cells was analysed by
flow cytometry. Antibody titres were calculated based on delta
mean fluorescence intensity (DMFI) of LN18
AQP4 vs LN18
CTR.
Histology
Mice were sacrificed using CO2. Histology was performed as
described recently [33,34]. Spinal cords including spinal canal and
optic nerves were removed and fixed in 4% buffered formalin.
Then, spinal cords were dissected and embedded in paraffin
before staining with luxol fast blue (LFB) to assess the degree of
demyelination, anti-MAC-3 (BD Biosciences) for assessment of
macrophages/microglia infiltrates, and anti-CD3 for assessment of
T cell infiltrates (Serotec).
Statistical analysis
Statistical evaluations of cell frequency measurements and
proliferation data were performed using the unpaired Student’s t-
test. For comparison of clinical EAE scores, the Mann-Whitney U
rank sum test was used. P values,0.05 were considered significant.
Author Contributions
Conceived and designed the experiments: BH TK. Performed the
experiments: SRK VR OS RS FP MP. Analyzed the data: SRK VR OS
RS FP MP TK. Contributed reagents/materials/analysis tools: BH TK.
Wrote the paper: TK SRK.
References
1. Devic E (1894) Mye ´lite subaigue ¨ complique ´e de ne ´vrite optique. Bull Med (Paris)
8: 1033–1034.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al.
(2004) A serum autoantibody marker of neuromyelitis optica: distinction from
multiple sclerosis. Lancet 364: 2106–2112.
3. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker
of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp
Med 202: 473–477.
4. Verkman AS (2009) Aquaporins: translating bench research to human disease.
Journal of Experimental Biology 212: 1707–1715.
5. Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, et al. (2000) Aquaporin-4
deletion in mice reduces brain edema after acute water intoxication and
ischemic stroke. Nature Medicine 6: 159–163.
6. Papadopoulos MC, Manley GT, Krishna S, Verkman AS (2004) Aquaporin-4
facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB Journal
18: 1291–1293.
7. Lu M, Lee MD, Smith BL, Jung JS, Agre P, et al. (1996) The human AQP4 gene:
definition of the locus encoding two water channel polypeptides in brain. Proceedings of
the National Academy of Sciences of the United States of America 93: 10908–10912.
8. Crane JM, Verkman AS (2009) Determinants of aquaporin-4 assembly in
orthogonal arrays revealed by live-cell single-molecule fluorescence imaging.
Journal of Cell Science 122: 813–821.
9. Furman CS, Gorelick-Feldman DA, Davidson KG, Yasumura T, Neely JD,
et al. (2003) Aquaporin-4 square array assembly: opposing actions of M1 and
M23 isoforms. Proceedings of the National Academy of Sciences of the United
States of America 100: 13609–13614.
Aquaporin-4 Specific T Cell Responses
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e1608310. Saini H, Fernandez G, Kerr D, Levy M (2010) Differential expression of
aquaporin-4 isoforms localizes with neuromyelitis optica disease activity. Journal
of Neuroimmunology 221: 68–72.
11. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, et al. (2007) Anti-
aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on
antibody titre. Brain 130: 1235–1243.
12. Jarius S, Franciotta D, Bergamaschi R, Wildemann B, Wandinger KP (2010)
Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and
related disorders. Clinical Chemistry and Laboratory Medicine 48: 659–663.
13. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG
(2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:
1485–1489.
14. Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, et al. (2007)
Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple
sclerosis in Japanese. Brain 130: 1206–1223.
15. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, et al. (2007)
Pathogenic potential of IgG binding to water channel extracellular domain in
neuromyelitis optica. Neurology 69: 2221–2231.
16. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, et al. (2002)
Plasma exchange for severe attacks of CNS demyelination: predictors of
response. Neurology 58: 143–146.
17. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, et al. (2002) A
role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis
optica. Brain 125: 1450–1461.
18. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, et al. (2007) Loss of
aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
Brain 130: 1224–1234.
19. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR,
et al. (2006) Neuromyelitis optica brain lesions localized at sites of high
aquaporin 4 expression. Archives of Neurology 63: 964–968.
20. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, et al. (2007)
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyeli-
tis optica from multiple sclerosis. Brain 130: 1194–1205.
21. Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, et al. (2009) Intrathecal
pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Annals of
Neurology 66: 617–629.
22. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, et al. (2009)
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Annals
of Neurology 66: 630–643.
23. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, et al. (2010) Intra-
cerebral injection of neuromyelitis optica immunoglobulin G and human
complement produces neuromyelitis optica lesions in mice. Brain 133: 349–361.
24. Snapper CM, Paul WE (1987) Interferon-gamma and B cell stimulatory factor-1
reciprocally regulate Ig isotype production. Science 236: 944–947.
25. Toellner KM, Luther SA, Sze DM, Choy RK, Taylor DR, et al. (1998) T helper
1 (Th1) and Th2 characteristics start to develop during T cell priming and are
associated with an immediate ability to induce immunoglobulin class switching.
Journal of Experimental Medicine 187: 1193–1204.
26. Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, et al. (2010) Quantification
and functional characterization of antibodies to native aquaporin 4 in
neuromyelitis optica. Archives of Neurology 67: 1201–1208.
27. Mitsdoerffer M, Lee Y, Jager A, Kim HJ, Korn T, et al. (2010) Proinflammatory
T helper type 17 cells are effective B-cell helpers. Proceedings of the National
Academy of Sciences of the United States of America 107: 14292–14297.
28. Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, et al. (2010) Anti-
aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS
antigen-specific T cells. Biochemical and Biophysical Research Communications
394: 205–210.
29. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A (2006) Spontaneous
opticospinal encephalomyelitis in a double-transgenic mouse model of
autoimmune T cell/B cell cooperation. J Clin Invest 116: 2385–2392.
30. Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK (2006) Myelin
oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a
Devic-like disease in mice. J Clin Invest 116: 2393–2402.
31. Pollinger B, Krishnamoorthy G, Berer K, Lassmann H, Bosl MR, et al. (2009)
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive
transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 206:
1303–1316.
32. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, et al. (2003) Myelin
oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop
spontaneous autoimmune optic neuritis. J Exp Med 197: 1073–1081.
33. Mildner A, Mack M, Schmidt H, Bruck W, Djukic M, et al. (2009) CCR2+Ly-
6Chi monocytes are crucial for the effector phase of autoimmunity in the central
nervous system. Brain 132: 2487–2500.
34. Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, et al. (2006) Innate
immunity mediated by TLR9 modulates pathogenicity in an animal model of
multiple sclerosis. Journal of Clinical Investigation 116: 456–464.
Aquaporin-4 Specific T Cell Responses
PLoS ONE | www.plosone.org 11 January 2011 | Volume 6 | Issue 1 | e16083